Search

Author/Creator Hynes, Scott M.

1. A Phase 1b trial of prexasertib in combination with chemoradiation in patients with locally advanced head and neck squamous cell carcinoma. (April 2021)

Authors:
Yang, Eddy S.; Deutsch, Eric; Mehmet, Altan; Fayette, Jerome; TAO, Yungan; Nabell, Lisle; Spencer, Sharon A.; Wang, Xuejing A.; Spoljoric, Elizabeth A.; Zhang, Wei; Hynes, Scott M.; Decker, Rodney L.; Lin, Aimee K. Bence; William, William N.
Journal:
Radiotherapy and oncology
Issue:
Volume 157(2021)
Page Start:
203
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. A randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non‐small cell lung cancer. (June 2017)

Authors:
Wehler, Thomas; Thomas, Michael; Schumann, Christian; Bosch-Barrera, Joaquim; Viñolas Segarra, Nuria; Dickgreber, Nicolas J.; Dalhoff, Klaus; Sebastian, Martin; Corral Jaime, Jesus; Alonso, Miriam; Hynes, Scott M.; Lin, Ji; Hurt, Karla; Bence Lin, Aimee; Calvo, Emiliano; Paz-Ares, Luis
Journal:
Lung cancer
Issue:
Volume 108(2017)
Page Start:
212
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Disposition and metabolism of LY2603618, a Chk-1 inhibitor following intravenous administration in patients with advanced and/or metastatic solid tumors. (September 2014)

Authors:
Wickremsinhe, Enaksha R.; Hynes, Scott M.; Palmieri, Margo D.; Mitchell, Malcolm I.; Abraham, Trent L.; Rehmel, Jessica Fayer; Chana, Emilie; Jost, Lorenz M.; Cassidy, Kenneth C.
Journal:
Xenobiotica
Issue:
Volume 44:Number 9(2014:Sep.)
Page Start:
827
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Evaluation of the likelihood of a selective CHK1 inhibitor (LY2603618) to inhibit CYP2D6 with desipramine as a probe substrate in cancer patients. (14th November 2014)

Authors:
Hynes, Scott M.; Wickremsinhe, Enaksha; Zhang, Wei; Decker, Rodney; Ott, Jennifer; Chandler, Jason; Mitchell, Malcolm
Journal:
Biopharmaceutics & drug disposition
Issue:
Volume 36:Number 1(2015:Jan.)
Page Start:
49
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Phase I study of LY2603618, a CHK1 inhibitor, in combination with gemcitabine in Japanese patients with solid tumors. Issue 10 (November 2015)

Authors:
Doi, Toshihiko; Yoshino, Takayuki; Shitara, Kohei; Matsubara, Nobuaki; Fuse, Nozomu; Naito, Yoichi; Uenaka, Kazunori; Nakamura, Takashi; Hynes, Scott M.; Lin, Aimee Bence
Journal:
Anti-cancer drugs
Issue:
Volume 26:Issue 10(2015)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Phase I study of LY2603618, a CHK1 inhibitor, in combination with gemcitabine in Japanese patients with solid tumors. Issue 10 (November 2015)

Authors:
Doi, Toshihiko; Yoshino, Takayuki; Shitara, Kohei; Matsubara, Nobuaki; Fuse, Nozomu; Naito, Yoichi; Uenaka, Kazunori; Nakamura, Takashi; Hynes, Scott M.; Lin, Aimee Bence
Journal:
Anti-cancer drugs
Issue:
Volume 26:Issue 10(2015)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗